Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

نویسندگان

چکیده

Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases, rheumatoid arthritis (RA), and antineutrophil cytoplasmic antibody-associated vasculitis. Treatment ILD, mainly based on immunosuppression, remains challenging. Rituximab (RTX), monoclonal antibody binding to CD20, is considered valuable therapeutic choice in cases refractory ILD. Here, we review the available efficacy safety data use RTX treatment rheumatic disease-related Despite controversial data, seems be able stabilize or improve ILD related RA antisynthetase syndrome established complicating systemic sclerosis. Fewer are regarding Sjogren syndrome, lupus erythematosus, To date, few prospective studies randomized trials still ongoing with purpose exploring role this condition, including supposed relationship between radiologic patterns up now derived from studies. an overall acceptable profile, concerns remain increased infectious risk patients as well possible toxicity rate immune-mediated reactions diseases. In conclusion, relevant option for despite existing uncertainties; expected clarify its use.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effects of rituximab in connective tissue disorders related interstitial lung disease.

OBJECTIVES Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy. METHODS A multicentre retrospecti...

متن کامل

Interstitial lung disease in connective tissue disorders.

Some of the most pressing challenges associated with interstitial lung disease (ILD) are how best to define, diagnose, and treat connective tissue disease-associated ILD (CTD-ILD)--disorders with potentially substantial morbidity and mortality. In this focused review, we address aspects of prognosis for CTD-ILD and what indices might predict outcome, together with lessons that can be learnt fro...

متن کامل

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.

In very severe interstitial lung disease associated with connective tissue disease (CTD-ILD), progressing despite maximal conventional immunosuppression, there is no effective medical rescue therapy. The aim of the present study was to test whether rituximab, a monoclonal antibody that depletes peripheral B lymphocytes, is effective as rescue therapy in very severe CTD-ILD, unresponsive to conv...

متن کامل

The Assessment of Health-Related Quality of Life in Scleroderma-Interstitial Lung Disease

Introduction: Pulmonary involvement is the most common cause of mortality and disability in patients with systemic sclerosis and it significantly affects the quality of life in these patients. Therefore, early diagnosis and treatment of pulmonary involvement seems necessary in patients with SSc. In this study, we aimed to assess the health-related quality of life (HRQoL) in patients with Sclero...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Drugs in context

سال: 2021

ISSN: ['1745-1981', '1740-4398']

DOI: https://doi.org/10.7573/dic.2020-8-7